Jyothy Labs Ltd (JYOTHYLAB)

Fast Moving Consumer Goods · FMCG · NSE · Updated 2 September 2026
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
₹204.9 ↓ 39.23% (1Y)

🎯 Key Takeaways

  • Jyothy Labs is in a transitional phase marked by modest top-line growth amid persistent margin pressure from elevated input costs, despite resilient volume trends in core segments like Fabric and Home Care. Management is focused on margin recovery through pricing discipline and innovation, while navigating a challenging macro environment with crude-linked inflation.
  • Revenue declined 5.3% QoQ to ₹667 in Q4FY25.
  • ⚠️ Persistent input cost inflation from crude-linked raw materials continues to pressure gross margins, with management's H2 FY27 recovery contingent on
Market Cap
₹7,524
P/E Ratio
20.3
P/B Ratio
3.67
ROE
18.1%
ROCE
24.1%
Debt/Equity
0.00
Div Yield
1.71%
Promoter
62.9%

📖 The Story

Jyothy Labs is in a transitional phase marked by modest top-line growth amid persistent margin pressure from elevated input costs, despite resilient volume trends in core segments like Fabric and Home Care. Management is focused on margin recovery through pricing discipline and innovation, while navigating a challenging macro environment with crude-linked inflation. The company maintains a strong balance sheet with zero net debt and consistent cash generation, but recent profit declines and share price weakness (-39.91% 1Y return) reflect market skepticism about near-term earnings visibility.

📰 What's Happening

In Q1 FY27 (reported August 12, 2026), revenue grew 3.0% YoY to ₹773 crores, driven by 8.1% value growth in core segments excluding Pril and Fa, with Fabric Care up 14.1% and Home Care up 2.4%. However, PAT declined sharply to ₹47.6 crores from prior periods, reflecting margin compression. The Board approved transferring the Jammu facility leasehold rights to Aikyam Flexipack for ₹9.93 crores in August 2026, targeting completion by March 31, 2027, potentially freeing up capital but reducing manufacturing footprint. At the July 14, 2026 AGM, shareholders approved the audited FY26 results and a final dividend of ₹3.50 per share, while endorsing strategic focus on the Exo brand and ESG initiatives.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

MetricJun 2024Sep 2024Dec 2024Mar 2025
Revenue742734704667
Operating Profit12012510197
OPM %16.2%17.0%14.4%14.6%
Net Profit1021058776
EPS₹2.77₹2.86₹2.38₹2.08

Quarterly revenue has shown a gradual decline from ₹742 crores in June 2024 to ₹667 crores in March 2025, despite stable operating margins around 14-16%. Net profit has also trended downward from ₹105 crores in September 2024 to ₹76 crores in March 2025, with EPS falling from ₹2.86 to ₹2.08 over the same period. This trend aligns with management's commentary on margin pressure from 30-35% crude-linked input cost inflation, which reduced gross margins from 48% to 38% in Q1 FY27. While volume growth remains positive in core segments, the sequential decline in profitability suggests that cost inflation is outpacing pricing gains, even as management targets H2 FY27 margin recovery contingent on crude stabilization.

🔮 Management Outlook & What's Next

Management expects margin improvement in the second half of FY27 as input cost inflation moderates, supported by innovation, premiumisation, and calibrated pricing actions. They highlighted that pricing increases of 3% were implemented in Q1 FY27, with plans for further calibrated hikes, and emphasized double-digit revenue growth targets for FY27 excluding Pril and Fa. However, no specific revenue or margin targets were provided during the concall on June 30, 2026. The focus remains on sustaining volume growth in modern trade, e-commerce, and quick commerce channels, while developing the Exo brand as an owned platform for long-term differentiation and margin expansion.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

ItemMar 2024Mar 2024Mar 2025Mar 2025
Equity Capital37373737
Reserves1,6031,7721,8492,013
Borrowings4551560
Total Liabilities2,2202,4012,5262,691
Fixed Assets3253333371,141
Investments5192288456
Total Assets2,2202,4012,5262,691

The balance sheet remains exceptionally strong with zero net debt and consistently rising equity and reserves over the past three fiscal years. As of March 2025, total assets stood at ₹2,691 crores with equity of ₹37 crores and reserves of ₹2,013 crores, up from ₹1,772 crores in March 2024. Borrowings remain minimal at ₹56 crores in March 2025, down from ₹51 crores a year earlier, indicating no leverage increase. This financial discipline supports strategic flexibility, including the recent ₹9.93 crore asset transfer, but the lack of debt also limits financial engineering options to offset margin pressures.

💰 Cash Flow Statement (₹ Cr)

ItemMar 2025
Operating+311
Investing-161
Financing-157
Net Cash Flow-7

👥 Shareholding Pattern

CategoryQ2FY26Q3FY26Q4FY26Q1FY27
Promoters62.9%62.9%62.9%62.9%
FII12.1%12.8%12.3%12.1%
DII16.1%15.1%14.6%13.4%
Public7.6%7.8%8.6%9.9%
# Shareholders2,17,3052,23,8012,33,3142,47,104

Institutional investor interest has remained relatively stable, with FII holding at 12.13% in Q1 FY27 (down slightly from 12.35% in Q4 FY26), while DII holdings declined from 16.08% in Q2 FY26 to 13.37% in Q1 FY27. Promoter holding remains steady at 62.89% across all quarters. The growing number of shareholders — from 2,17,305 in Q2 FY26 to 2,47,104 in Q1 FY27 — suggests retail participation is increasing, possibly reflecting retail investor confidence or index inclusion. However, the sustained promoter stake and stable institutional holdings indicate no major shifts in ownership structure despite share price declines.

⚖️ Peer Comparison — FMCG

Company MCap (₹ Cr) P/E ROCE ROE D/E
HINDUNILVR 4.69 L Cr 31.3 29.8% 30.7% 0.00
ITC 3.34 L Cr 16.8 36.0% 27.8% 0.03
NESTLEIND 2.78 L Cr 73.0 99.2% 73.9% 0.00
VBL 1.37 L Cr 40.6 21.5% 17.4% 0.10
BRITANNIA 1.25 L Cr 47.9 54.1% 51.1% 0.27
LENSKART 1.15 L Cr 173.3 11.9% 7.7% 0.03
MARICO 1.09 L Cr 57.3 54.2% 46.4% 0.08
TATACONSUM 1.02 L Cr 62.2 10.2% 8.0% 0.10
GODREJCP 92,112 48.1 17.8% 15.1% 0.33
DABUR 68,173 34.6 21.3% 17.1% 0.09

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Persistent input cost inflation from crude-linked raw materials continues to pressure gross margins, with management's H2 FY27 recovery contingent on crude price stability — a material uncertainty. 2. Margin compression is evident in both EBITDA (8.4% in Q1 FY27 vs historical 18-20%) and PAT trends, with no clear timeline for full recovery despite pricing actions. 3. Core segment growth is decelerating in Home Care (2.4% excluding Pril), raising concerns about volume sustainability. 4. The sale of the Jammu facility, while capital-light, may reduce operational capacity and is not a scalable solution to margin challenges.

📋 Recent Filings

🧠 Analyst's Read

Jyothy Labs is navigating a critical inflection point where margin recovery hinges on crude price trends and successful execution of pricing and innovation strategies. While the strong balance sheet and resilient core segments provide a foundation, the declining profitability and share price performance underscore execution risks. Investors should monitor H2 FY27 margin trends, crude input cost developments, and the pace of Exo brand monetization as key near-term catalysts.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

Sign Up Free — Unlock Full Analysis

2 free AI queries per day.

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when JYOTHYLAB files new disclosures

Track JYOTHYLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track JYOTHYLAB — Free

Free account · 2 AI queries/day